Multiple Myeloma Hub

During the American Society of Clinical Oncology (ASCO) 2020 Meeting, the Multiple Myeloma Hub was pleased to speak to Enrique M. Ocio, Marqués de Valdecilla University Hospital, Santander, ES. In this podcast, Enrique M. Ocio discusses the results of the phase I/II trial that evaluated quadruplet combinations in patients with transplant-ineligible multiple myeloma.

Enrique M. Ocio begins by describing how first-line treatments for this population of patients have changed recently, and then provides results from a study investigating the use of isatuximab (an anti-CD8 monoclonal antibody) in combination with quadruplet regimens; bortezomib + cyclophosphamide + dexamethasone (VCd) or bortezomib + lenalidomide + dexamethasone (VRd). He provides efficacy, safety and tolerably data as well as measurable residual disease analysis, and concludes with his perspective on which treatments should be used for elderly patients.

Hosted on Acast. See acast.com/privacy for more information.

During COMy 2020, Paula Rodriguez Otero, Clínica Universidad de Navarra, Pamplona, ES, spoke to the Multiple Myeloma (MM) Hub. We asked: How should we treat elderly patients with newly diagnosed MM? 

A number of factors may influence a patient's eligibility for, and outcome to, different treatments in the MM setting. Here, Paula Rodriguez Otero discusses these factors and outlines the available treatment options for patients deemed ineligible for transplant.

Hosted on Acast. See acast.com/privacy for more information.

During COMy 2020, Enrique Ocio, Marqués de Valdecilla University Hospital, Santander, ES, spoke to the Multiple Myeloma (MM) Hub about resistance mechanisms to current standard of care and how to overcome them.

Although advances in treatment options for MM have improved the outcome of patients in recent years, resistance remains a problem and MM is still considered an incurable disease. Here, Enrique Ocio discusses the importance of understanding the mechanisms behind both primary and secondary resistance in order to overcome them.

Hosted on Acast. See acast.com/privacy for more information.

During COMy 2020, Artur Jurczyszyn, Jagiellonian University Medical College, Krakow, PL, spoke to the Multiple Myeloma Hub. We asked: What is plasma cell leukemia and what are the latest advances in treatment?

In this podcast, Artur Jurczyszyn talks about the classifications of plasma cell leukemia and the importance of outlining a plasma cell prognostic index for use in clinical practice. The data from two retrospective analyses, evaluating primary and secondary plasma cell leukemia, are discussed.

Hosted on Acast. See acast.com/privacy for more information.